Justice Department eases restrictions on some marijuana products

The Justice Department has announced a significant change in the classification of certain marijuana products, moving them to a lower drug classification under the Controlled Substances Act. Acting Attorney General Todd Blanche signed an order that places FDA-approved marijuana products and those regulated by state medical marijuana licenses into Schedule III, which indicates a moderate to low potential for dependence. This move aligns with an executive order from President Trump, aiming to expand access to medical treatments. The Justice Department and the Drug Enforcement Administration are also expediting a process to consider reclassifying marijuana more broadly from Schedule I, the strictest category, to Schedule III. This reclassification acknowledges state regulations on medical marijuana and aims to facilitate research on its safety and efficacy. However, marijuana not covered by FDA approval or state licenses remains a Schedule I substance, subject to strict controls and penalties. QUESTION: How might the reclassification of marijuana products impact the future of medical research and treatment options?